1/2 CATHETER-DIRECTED THERAPY FOR CHRONIC DVT (C-TRACT TRIAL)
慢性 DVT 的 1/2 导管导向治疗(C-TRACT 试验)
基本信息
- 批准号:10685552
- 负责人:
- 金额:$ 121.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAcuteAnatomyAwardBlindedBlood flowCaringCathetersChronicChronic CareChronic PhaseClinicalClinical TrialsCollaborationsComplicationCustodial CareDeep Vein ThrombosisDiseaseEdemaEffectivenessExcisionGrantHealthHealth Care CostsHemorrhageIliac VeinImageImpairmentInterventionLeg UlcerLifeLower ExtremityMeasuresMedicalMedical Care CostsMissionModelingNational Heart, Lung, and Blood InstituteObservational StudyObstructionOdds RatioOutcome StudyPainPain in lower limbParticipantPatientsPhysiologicalPostphlebitic SyndromePrediction of Response to TherapyProcessProductivityPublic HealthQuality of lifeRandomized, Controlled TrialsRecurrenceRefluxResearchResource DevelopmentRiskSF-36SafetySecondary toSeveritiesSocietiesStandardizationStasis dermatitisStentsSwellingTestingThrombosisThrombusUlcerVaricose UlcerVeinsVenousVenous ThrombosisWorkarmcare costsclaudicationclinical practicecostcost effective treatmentcost effectivenesscost per quality-adjusted life yeardaily functioningdisabilityeconomic evaluationeffectiveness evaluationevidence baseexperiencefollow-uphealinghealth economicshealth related quality of lifeimage guidedimprovedincremental cost-effectivenessopen labelpreventprimary outcomerandomized trialsecondary outcomeskin ulcerthrombolysistreatment strategytrial planning
项目摘要
PROJECT SUMMARY
The post-thrombotic syndrome (PTS) is a permanent complication of lower extremity deep vein thrombosis
(DVT). Patients with moderate-to-severe PTS secondary to chronic iliac vein obstruction experience
profound disability and quality of life impairment from pain, massive edema, stasis dermatitis, and/or venous
leg ulcers ("Disabling Iliac-Obstructive PTS" [DIO-PTS]). Currently, there is no evidence-based therapy for
DIO-PTS. Observational studies and a small single-center randomized trial suggest that imaging-guided,
catheter-based endovascular therapy (EVT) that eliminates iliac vein obstruction (stent placement) and
saphenous venous valvular reflux (endovenous ablation) is effective. However, EVT has risks and is costly.
We therefore plan to do an open-label, assessor-blinded, multicenter, randomized controlled trial (the
Chronic Venous Thrombosis: Relief with Adjunctive Catheter-Directed Therapy (C-TRACT) Study)
that will compare EVT with No-EVT in 374 patients with DIO-PTS. All patients will receive optimal
standardized medical therapy for PTS. The primary outcome will be within-subject improvement in PTS
severity over 6 months, assessed blindly using the Venous Clinical Severity Score (VCSS). Secondary
outcomes include PTS severity (VCSS, Villalta, ulcer healing), and venous disease-specific (VEINES-QOL)
and generic (SF-36) quality of life at 6 and 24 months. A comprehensive health economic analysis will
compare medical costs and estimate the incremental cost-effectiveness of EVT. Safety (e.g. bleeding,
recurrent thrombosis) will be assessed at 2, 6, and 24 months, and venous imaging will be performed to
identify anatomic and physiologic predictors of therapeutic response. The C-TRACT Study will change
clinical practice: if EVT is effective and safe, it will become part of standard therapy for DIO-PTS; if not, a
risky and costly therapy will be avoided. Hence, either study outcome will improve public health and
advance the NHLBI’s mission.
项目摘要
血栓后综合征(PTS)是下肢深静脉血栓形成的永久性并发症
(DVT)。继发于慢性髂静脉阻塞的中重度PTS患者的经验
疼痛、大量水肿、淤滞性皮炎和/或静脉性皮炎导致严重残疾和生活质量受损
腿部溃疡(“致残性髂动脉阻塞性PTS”[DIO-PTS])。目前,没有循证治疗,
DIO-PTS。观察性研究和一项小型单中心随机试验表明,
基于导管的血管内治疗(EVT),消除髂静脉阻塞(支架置入),
隐静脉瓣膜反流(静脉内消融)是有效的。然而,EVT具有风险且成本高。
因此,我们计划进行一项开放标签、评估者盲法、多中心、随机对照试验(
慢性静脉血栓形成:辅助导管引导治疗缓解(C-TRACT)研究
将在374例DIO-PTS患者中比较EVT与无EVT。所有患者将接受最佳
PTS的标准化药物治疗。主要结局为受试者内PTS改善
使用静脉临床严重程度评分(VCSS)盲法评估6个月内的严重程度。二次
结局包括PTS严重程度(VCSS、Villalta、溃疡愈合)和静脉疾病特异性(VEINES-QOL)
以及6个月和24个月时的一般(SF-36)生活质量。全面的卫生经济分析将
比较医疗成本,并估计EVT的增量成本效益。安全性(例如出血,
复发性血栓形成)将在2、6和24个月时进行评估,并进行静脉成像,
识别治疗反应的解剖学和生理学预测因素。C-TRACT研究将发生变化
临床实践:如果EVT是有效和安全的,它将成为DIO-PTS的标准治疗的一部分;如果不是,
将避免危险和昂贵的治疗。因此,任何一项研究结果都将改善公众健康,
推进NHLBI的使命。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Delphi Consensus on Reporting Standards in Clinical Studies for Endovascular Treatment of Acute Iliofemoral Venous Thrombosis and Chronic Iliofemoral Venous Obstruction.
- DOI:10.1161/circinterventions.123.012894
- 发表时间:2023-07
- 期刊:
- 影响因子:5.6
- 作者:Vedantham, Suresh;Gloviczki, Peter;Carman, Teresa L.;Zelman Lewis, Sandra;Schneider, Peter A.;Sabri, Saher S.;Kolluri, Raghu
- 通讯作者:Kolluri, Raghu
Gastrointestinal Malignancies and Venous Thromboembolic Disease: Clinical Significance and Endovascular Interventions.
- DOI:10.1055/s-0040-1716739
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Li X;Partovi S;Gadani S;Martin C 3rd;Beck A;Vedantham S
- 通讯作者:Vedantham S
Society of Interventional Radiology Position Statement on the Management of Chronic Iliofemoral Venous Obstruction with Endovascular Placement of Metallic Stents.
介入放射学会关于血管内放置金属支架治疗慢性髂股静脉阻塞的立场声明。
- DOI:10.1016/j.jvir.2023.06.013
- 发表时间:2023
- 期刊:
- 影响因子:0
- 作者:Vedantham,Suresh;Weinberg,Ido;Desai,KushR;Winokur,Ronald;Kolli,KantiPallav;Patel,Sheena;Nelson,Kari;Marston,William;Azene,Ezana
- 通讯作者:Azene,Ezana
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SURESH VEDANTHAM其他文献
SURESH VEDANTHAM的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SURESH VEDANTHAM', 18)}}的其他基金
1/2 CATHETER-DIRECTED THERAPY FOR CHRONIC DVT (C-TRACT TRIAL)
慢性 DVT 的 1/2 导管导向治疗(C-TRACT 试验)
- 批准号:
10475574 - 财政年份:2017
- 资助金额:
$ 121.36万 - 项目类别:
1/2 CATHETER-DIRECTED THERAPY FOR CHRONIC DVT (C-TRACT TRIAL)
慢性 DVT 的 1/2 导管导向治疗(C-TRACT 试验)
- 批准号:
9998750 - 财政年份:2017
- 资助金额:
$ 121.36万 - 项目类别:
1/2 CATHETER-DIRECTED THERAPY FOR CHRONIC DVT (C-TRACT TRIAL)
慢性 DVT 的 1/2 导管导向治疗(C-TRACT 试验)
- 批准号:
9370853 - 财政年份:2017
- 资助金额:
$ 121.36万 - 项目类别:
1/2 CATHETER-DIRECTED THERAPY FOR CHRONIC DVT (C-TRACT TRIAL)
慢性 DVT 的 1/2 导管导向治疗(C-TRACT 试验)
- 批准号:
9552300 - 财政年份:2017
- 资助金额:
$ 121.36万 - 项目类别:
CHRONIC VENOUS THROMBOSIS: RELIEF WITH ADJUNCTIVE CATHETER-BASED THERAPY (C-TRACT
慢性静脉血栓形成:基于辅助导管的治疗(C-TRACT)缓解
- 批准号:
8757713 - 财政年份:2014
- 资助金额:
$ 121.36万 - 项目类别:
PHARMACOMECHANICAL CATHETER-DIRECTED THROMBOLYSIS FOR ACUTE DVT - ATTRACT TRIAL
药物机械导管定向溶栓治疗急性 DVT - ATTRACT 试验
- 批准号:
7467111 - 财政年份:2008
- 资助金额:
$ 121.36万 - 项目类别:
PHARMACOMECHANICAL CATHETER-DIRECTED THROMBOLYSIS FOR ACUTE DVT - ATTRACT TRIAL
药物机械导管定向溶栓治疗急性 DVT - ATTRACT 试验
- 批准号:
8474823 - 财政年份:2008
- 资助金额:
$ 121.36万 - 项目类别:
PHARMACOMECHANICAL CATHETER-DIRECTED THROMBOLYSIS FOR ACUTE DVT - ATTRACT TRIAL
药物机械导管定向溶栓治疗急性 DVT - ATTRACT 试验
- 批准号:
7826595 - 财政年份:2008
- 资助金额:
$ 121.36万 - 项目类别:
PHARMACOMECHANICAL CATHETER-DIRECTED THROMBOLYSIS FOR ACUTE DVT - ATTRACT TRIAL
药物机械导管定向溶栓治疗急性 DVT - ATTRACT 试验
- 批准号:
8077310 - 财政年份:2008
- 资助金额:
$ 121.36万 - 项目类别:
PHARMACOMECHANICAL CATHETER-DIRECTED THROMBOLYSIS FOR ACUTE DVT - ATTRACT TRIAL
药物机械导管定向溶栓治疗急性 DVT - ATTRACT 试验
- 批准号:
7633389 - 财政年份:2008
- 资助金额:
$ 121.36万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 121.36万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 121.36万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 121.36万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 121.36万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 121.36万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 121.36万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 121.36万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 121.36万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 121.36万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 121.36万 - 项目类别:
Operating Grants